- On February 16, Healthcare Design magazine offered a “first look” at MSK’s new fifteen-floor Josie Robertson Surgery Center building (designed by Perkins Eastman) currently being built in New York and scheduled to open in 2016. The article highlights the work of Icrave, the studio providing “experiential design and programming for the building”.
- On February 4, the Business Insider described how IBM’s Watson computer system (that famously won Jeopardy!) is proving valuable to doctors. For cancer, MSK has helped IBM develop Watson for Oncology, a platform that helps physicians narrow down what is clinically relevant from mounds of patient data.
- In a February 16 article in The Journal News, Dr. Chau Dang, chief of medical oncology at MSKCC’s new treatment center in West Harrison, provided insights into the promise of immunotherapy for fighting cancer.
- On February 5, HCPLive highlighted a recent publication in the Journal of Clinical Oncology by MSK’s Dr. William Breitbart and his colleagues . Their randomized controlled study showed that Meaning-Centered Group Psychotherapy (MCGP) is effective at reducing psychological and spiritual distress in patients with advanced cancer.
Category Archives: MSK in the News
Joan Massagué co-winner of the 2015 Charles Rodolphe Brupbacher Prize and more…
Some mentions of MSK in the news lately;
- MSK’s Joan Massagué, and Irving L. Weissman of Stanford University, were awarded the Charles Rodolphe Brupbacher Prize for their contributions to cancer research. The prizes (each worth CHF 100,000) were presented at the “Breakthroughs in Cancer Research and Therapy” symposium in Zurich.
- In a study published January 27, MSK’s Dr. Michael Zelefsky and colleagues determined that the likelihood of surviving prostate cancer for 10 recurrence-free years was 66.4 % among patients who had never smoked, 62.6 % for former smokers, and only 52.4 % among patients who were current smokers.
- In a JAMA Dermatology paper, MSK’s Xinyuan Wu and co-authors reported on their study that showed it is feasible and effective to monitor patients’ moles via teledermoscopy over a short-term period.
Saying “No” to High Drug Costs and More…
- In his January 14 editorial in the NYTimes, MSK’s Dr. Peter B. Bach questioned the wisdom of legally requiring insurance companies and government programs to include coverage in their policies for all drugs, even prohibitively expensive ones, as we do in the United States. He described how just saying “no” has led to lower drug costs in other countries and even in a few cases in the US, in which a company, or in the case of MSK, a hospital, has taken a stand.
- MSK recently partnered with Enumeral Biomedical Holdings, Inc. on a two-year project supported by a $999,967 Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute. In the project, Dr. Jedd D. Wolchok and his team will use an advanced, automated prototype system for human tissue immuno-oncology profiling developed by Enumeral.